Detalhe da pesquisa
1.
Pathogenic germline variants in patients with endometrial cancer of diverse ancestry.
Cancer
; 130(4): 576-587, 2024 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37886874
2.
Molecular and pathologic data to guide selection of patients with endometrioid endometrial cancer for ovarian preservation.
Int J Gynecol Cancer
; 34(5): 697-704, 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38508587
3.
The highs and lows of serous ovarian cancer.
Cancer
; 129(17): 2613-2620, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366225
4.
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Cancer
; 129(13): 2004-2012, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951509
5.
Molecular subtyping in endometrial cancer: A promising strategy to guide fertility preservation.
Gynecol Oncol
; 179: 180-187, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37992549
6.
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Gynecol Oncol
; 170: 93-101, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36669327
7.
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol
; 176: 69-75, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37454565
8.
Validation of claims-based algorithms to identify non-live birth outcomes.
Pharmacoepidemiol Drug Saf
; 32(4): 468-474, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36420643
9.
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
Gynecol Oncol
; 164(1): 12-17, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34763937
10.
Risk factors for financial toxicity in patients with gynecologic cancer.
Am J Obstet Gynecol
; 226(6): 817.e1-817.e9, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34902319
11.
Patient-reported benefit from proposed interventions to reduce financial toxicity during cancer treatment.
Support Care Cancer
; 30(3): 2713-2721, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34822002
12.
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.
Int J Gynecol Cancer
; 32(8): 1017-1024, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545291
13.
Demographic shifts associated with implementation of evidence-based guidelines for ovarian conservation in patients with endometrioid endometrial cancer.
Int J Gynecol Cancer
; 2022 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35831030
14.
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation.
Int J Gynecol Cancer
; 32(12): 1576-1582, 2022 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36368707
15.
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer.
Ann Surg Oncol
; 28(11): 6705-6713, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33683525
16.
Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Gynecol Oncol
; 162(2): 345-352, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34045053
17.
Diagnosis and management of an endometrial cancer patient with Cowden syndrome.
Gynecol Oncol
; 163(1): 14-21, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34446268
18.
Predictive validity of American College of Surgeons: National Surgical Quality Improvement Project risk calculator in patients with ovarian cancer undergoing interval debulking surgery.
Int J Gynecol Cancer
; 31(10): 1356-1362, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34518239
19.
Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer.
Int J Gynecol Cancer
; 31(10): 1341-1347, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34429355
20.
Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
Gynecol Oncol
; 159(3): 687-691, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32951891